Health

Nuclear medicine can facilitate the identification of cardiac amyloidosis, a pathology on the rise

3% of patients with bone scintigraphy have markers of cardiac amyloidosis, which can cause heart failure and increased mortality, according to a study by the American Society for Nuclear Medicine and Molecular Imaging (SNMMI). whose purpose was to estimate the prevalence of …



3% of patients with bone scintigraphy present markers of cardiac amyloidosis, which can cause heart failure and increased mortality, according to a study by the American Society for Nuclear Medicine and Molecular Imaging (SNMMI), whose purpose was to estimate the prevalence of cardiac amyloidosis in the general population based on bone scans and investigate associated outcomes.

Cardiac amyloidosis is a disease characterized by amyloid deposits taking the place of normal heart tissue, causing the heart becomes thicker and stiffer. Previously thought to be a rare condition, recent advances in diagnosis and awareness of the disease have led to an increasing number of cases of cardiac amyloidosis. Treatment of cardiac amyloidosis is more effective if given earlier in the disease. If not treated in time it can cause heart failure and even death of the patient.

Patients undergoing a nuclear medicine bone scan may have high levels of cardiac radiotracer uptake as an incidental finding, pointing to the presence of cardiac amyloidosis.“, exposed the Dr Christian Nitsche, trainee cardiologist and researcher at the Medical University of Vienna (Austria) and University College London (UK).

The research, whose results have been published in “The Journal of Nuclear Medicine”, is one of the first of its kind to identify the prevalence and outcomes of amyloidosis heart disease in the general population.



A total of 17,387 scans from 11,527 subjects, including both cardiac and non-cardiac leads, were analyzed for the study. All patients underwent cardiac radiotracer bone scintigraphy, and the scans were analyzed by nuclear medicine professionals. Visual assessments classified the scans as grade 0 (no DPD uptake), grade 1 (low-grade DPD uptake), and grade 2/3 (confirmed cardiac amyloidosis).

Among all subjects, 3.3 percent had some level of DPD acceptance (1.8 percent grade 1 and 1.5 percent grade 2/3). A prevalence of 1 in 50 was reported among noncardiac leads and 1 in 5 among cardiac leads. There was a significant increase in the prevalence of amyloidosis uptake with increasing age, and its associated comorbidities (such as arterial hypertension, coronary artery disease, and impaired renal function).

After follow-up for a period of six years, it was found that almost 30% of the participants had died. Cardiovascular death represented 8.9% of the cause of mortality. In addition, 1.5% of patients were hospitalized for heart failure during the follow-up period. Those with grade 2/3 amyloidosis uptake had a 3.5-fold increased risk of heart failure hospitalization compared with those with grade 0 uptake.

“Faced with worse outcomes and given the availability of new treatment options for cardiac amyloidosis, efforts to reliably diagnose amyloid uptake should be maximized.s,” said the Dr Andreas Kammerlandercan ardiologist at the Medical University of Vienna.Patients with cardiac amyloidosis uptake should be referred to a cardiology specialist for further evaluation, as early diagnosis may offer a window of opportunity to initiate cardiac amyloidosis treatments.“, from your point of view.

Given the availability of new tracers with high diagnostic accuracy, detection of cardiac amyloidosis can potentially be established purely non-invasive way in the future. “With the help of machine learning algorithms, automatic detection of cardiac amyloidosis based solely on planar images may represent another potential milestone in the field of molecular imaging.“, they concluded.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button